Physician profile
Anusha Valluru
NPI 1093761553
$2,299.21
in general payments reported to CMS, 2019-2025
32 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $190 · 2021: $349 · 2022: $288 · 2023: $377 · 2024: $457 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.04 | 2019-2021 | |
| Aspira Women'S Health INC | $344.49 | 2021-2025 | Ova1 |
| Hologic Sales and Service, LLC | $205.59 | 2019-2024 | Acessa Provu System |
| Exeltis, USA INC. | $185.92 | 2021-2025 | Slynd |
| Organon LLC | $175.92 | 2021-2025 | Nexplanon, Jada System |
| Merck Sharp & Dohme LLC | $95.83 | 2019-2024 | Gardasil 9, Gardasil |
| Pfizer INC. | $94.96 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $74.54 | 2021-2025 | |
| Astellas Pharma US INC | $66.61 | 2024 | Veozah |
| Coopersurgical, INC. | $56.21 | 2019-2023 | Paragard T 380a |
| Biogen, INC. | $55.11 | 2025 | Zurzuvae |
| Davol INC. | $51.16 | 2023-2025 | Arista Ah Flexitip, Arista |
| Lupin INC. | $48.59 | 2020-2021 | |
| Therapeuticsmd, INC. | $33.72 | 2022 | |
| Channel Medsystems, INC. | $33.22 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $33.12 | 2025 | |
| Abbott Laboratories | $33.02 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $32.60 | 2024-2025 | Dexcom G6 Transmitter |
| Myriad Women'S Health, INC. | $31.64 | 2023 | Myrisk |
| Ethicon US, LLC | $28.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.16 | 2021-2023 | |
| Shield Therapeutics INC | $26.47 | 2023 | Accrufer |
| Duchesnay USA Incorporated | $26.17 | 2019 | |
| Octapharma USA, INC. | $26.06 | 2025 | Fibryga |
| Millicent US INC | $24.04 | 2025 | Femlyv |
| Baxter Healthcare | $22.47 | 2024 | Tisseel |
| Axonics, INC. | $17.18 | 2024 | Axonics, Bulkamid |
| Mylan Pharmaceuticals INC. | $13.30 | 2021 | |
| Minerva Surgical, INC | $13.26 | 2023 | |
| Amgen INC. | $13.26 | 2023 | Prolia, Evenity |
| Mallinckrodt Enterprises LLC | $12.66 | 2019 | |
| Amag Pharmaceuticals, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anusha Valluru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.